Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Induction and Sirolimus Withdrawal in Kidney Transplant
NCT00078559Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2003
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in kidney transplant rejection, sponsored by University of Wisconsin–Madison. Primary endpoint: Number of Acute Rejections in All Enrolled Participants at 4 years. Started Nov 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00078559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078559.